By Josh White
Date: Thursday 04 Jan 2024
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said in a year-end update on Thursday that its primary focus remained on realising the full potential of its XF-73 Nasal asset.
Full year results and review of strategic options | 25-Apr-2024 | 07:00 | RNS |
Notice of Full Year Results | 08-Apr-2024 | 07:00 | RNS |
Exercise of Options and Total Voting Rights | 19-Mar-2024 | 14:47 | RNS |
Clinical development update | 31-Jan-2024 | 07:00 | RNS |
Appointment of Nominated Adviser and Sole Broker | 22-Jan-2024 | 07:00 | RNS |
No recent information was found.
No recent information was found.
No recent information was found.
Currency | UK Pounds |
Share Price | 18.00p |
Change Today | -0.25p |
% Change | -1.37 % |
52 Week High | 82.00 |
52 Week Low | 16.25 |
Volume | 225,759 |
Shares Issued | 95.31m |
Market Cap | £17.16m |
RiskGrade | 410 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:27 | 5,000 @ 17.68p |
16:25 | 10,000 @ 17.68p |
16:23 | 10,000 @ 18.18p |
16:13 | 20,000 @ 18.20p |
16:08 | 3,300 @ 18.21p |
You are here: research